PHAGEX-19 is a commercially distributed Nanophage Research augmentation substance. An institutional market report describes use across twelve cities and a rapid departure from ordinary human habits among recipients.[1]
Reported market
The report claims 3.2 million new dependent users in the preceding year, a $50 dose with a $2 production cost and twelve-percent monthly demand growth in the fourth quarter. It attributes $180 million in patent proceeds to the preceding quarter and $90 million over six months to a fifteen-percent secondary-market share. These are institutional financial claims, not independently audited totals.
Expansion plans
Detroit is reported to contain eighty thousand users producing $15 million in monthly revenue. The stated target is twenty million users by 2026, with a proposed $5 billion expansion into Asia. The target is not evidence that it was reached. The same designation appears in the dental-team catalogue, but a specific operational link is not described.
References
- Nanophage Research — PHAGEX-19 Primary post
Original account caption inspected directly on September 14th, 2026.